PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.

Deregulation of the phosphatidylinositol 3-kinase (PI3K) pathway either through loss of PTEN or mutation of the catalytic subunit alpha of PI3K (PIK3CA) occurs frequently in human cancer. We identified PIK3CA mutations in 26% of 342 human breast tumor samples and cell lines at about equal frequency in tumor stages I to IV. To investigate the relationship between PTEN and PIK3CA, we generated a cohort of tumors that had lost PTEN expression and compared it with a matched control set that had retained PTEN. A highly significant association between PIK3CA mutations and retention of PTEN protein expression was observed. In addition, PIK3CA mutations were associated with expression of estrogen and progesterone receptors (ER/PR), lymph node metastasis, and ERBB2 overexpression. The fact that PIK3CA mutations and PTEN loss are nearly mutually exclusive implies that deregulated phosphatidylinositol-3,4,5-triphosphate (PIP(3)) is critical for tumorigenesis in a significant fraction of breast cancers and that loss of PIP(3) homeostasis by abrogation of either PIK3CA or PTEN relieves selective pressure for targeting of the other gene. The correlation of PIK3CA mutation to ER/PR-positive tumors and PTEN loss to ER/PR-negative tumors argues for disparate branches of tumor evolution. Furthermore, the association between ERBB2 overexpression and PIK3CA mutation implies that more than one input activating the PI3K/AKT pathway may be required to overcome intact PTEN. Thus, mutation of PIK3CA is frequent, occurs early in carcinoma development, and has prognostic and therapeutic implications.

• Publication year

  2005

• Venue

  Cancer Research

• Publication date

  2005-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472-CAN-04-3913PMID 15805248
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The PIK3CA gene is mutated with high frequency in human breast cancers

  2004influential reference
• PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

  2004cited by this paper
• Mutation of the PIK3CA Gene in Ovarian and Breast Cancer

  2004cited by this paper
• Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels

  2004cited by this paper
• High Frequency of Mutations of the PIK3CA Gene in Human Cancers

  2004influential reference
• Regulation of Cell Migration by the C2 Domain of the Tumor Suppressor PTEN

  2004cited by this paper
• Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas

  2004cited by this paper
• PI 3-kinase, Akt and cell survival.

  2004cited by this paper
• Receptor-mediated regulation of PI3Ks confines PI(3,4,5)P3 to the leading edge of chemotaxing cells.

  2003cited by this paper
• c-erbB-2 in breast cancer: development of a clinically useful marker.

  2002cited by this paper
• Reduced expression of PTEN correlates with breast cancer progression.

  2002cited by this paper
• Loss of Expression of the PTEN Gene Protein Product Is Associated with Poor Outcome in Breast Cancer

  2001cited by this paper
• An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice

  2001cited by this paper
• PTEN: life as a tumor suppressor.

  2001cited by this paper
• PIK3CA as an oncogene in cervical cancer

  2000cited by this paper
• PIK3CA is implicated as an oncogene in ovarian cancer

  1999cited by this paper
• Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast.

  1999cited by this paper
• Infrequent Mutations in the PTEN/MMAC1 Gene among Primary Breast Cancers

  1998cited by this paper
• Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas.

  1997cited by this paper
• Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase.

  1997cited by this paper
• Role of steroid hormone receptors as prognostic factors in primary breast cancer.

  1986cited by this paper
• Pathological parameters useful in predicting prognosis for patients with breast cancer.

  1984cited by this paper

• Tissue-based genomic profiling of 300,000 tumors highlights the detection of variants with low allele fraction

  2025cites this paper
• Non-redundant roles of the phosphoinositide phosphatases PTEN and PIPP in PI3K/AKT signaling in breast cancer

  2025cites this paper
• Neoadjuvant Chemotherapy is Not Associated with Improved Overall Survival in Metaplastic Breast Cancer Regardless of Tumor Subtype

  2025cites this paper
• A comprehensive review on targeted therapies for triple negative breast cancer: an evidence-based treatment guideline

  2025cites this paper
• Modulation of the PI3K/Akt signaling pathway by resveratrol in cancer: molecular mechanisms and therapeutic opportunity

  2025cites this paper
• Clinicopathological and molecular significance of HER2-low expression in Asian women with triple-negative breast cancer

  2025cites this paper
• An update on promising and emerging protein kinase B/AKT inhibitors for breast cancer

  2025cites this paper
• Successful conversion surgery following tislelizumab with chemotherapy in a patient with stage IIIC lung adenocarcinoma harboring RET fusions: A case report and review of the literature

  2025cites this paper
• Time- and Dose-Dependent Effects of Irradiation on Endothelial and Tumor Endothelial Cells: Transcriptional, Molecular, and Functional Changes Driving Activation In Vitro and In Vivo

  2025cites this paper
• Unraveling hereditary breast cancer susceptibility: a systems biology approach on GEO datasets with functional genomic insights and implications for traditional Chinese medicine

  2025cites this paper
• Challenges and Prospects in HER2-Positive Breast Cancer-Targeted Therapy.

  2025cites this paper
• Emerging opportunities to treat drug-resistant breast cancer: Discovery of novel small-molecule inhibitors against different targets

  2025cites this paper
• Genomic landscape of estrogen receptor-positive HER2-negative advanced breast cancer with acquired resistance to aromatase inhibitors: Identification of an ESR1 alteration-related gene signature

  2025cites this paper
• Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study.

  2025cites this paper
• The Application of Liquid Biopsy for the Development and Validation of a Non-Invasive Screening and Diagnosis Test for Endometrial Premalignant and Malignant Lesions: A Prospective Innovative Pilot Study

  2025cites this paper
• US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.

  2025cites this paper
• Recent findings on the PD-1/PD-L1 Axis in breast cancer: Molecular mechanisms, immunotherapeutic potentials, and clinical implications.

  2025cites this paper
• IBI-DT: a novel approach combining individualized Bayesian inference and decision tree for identifying cancer drivers and their interactions

  2025cites this paper
• Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)

  2025cites this paper
• PI3K/AKT/mTOR Pathway in Breast Cancer Pathogenesis and Therapy: Insights into Phytochemical-Based Therapeutics

  2025cites this paper
• Characterizing the Tumor Microenvironment and Its Prognostic Impact in Breast Cancer

  2024cites this paper
• DNA methylation profiling deciphers three EMT subtypes with distinct prognoses and therapeutic vulnerabilities in breast cancer

  2024cites this paper
• EGFR and Hippo signaling pathways are involved in organophosphate esters–induced proliferation and migration of triple-negative breast cancer cells

  2024cites this paper
• Identification of phytomolecules as isoform and mutation specific PI3K-α inhibitor for protection against breast cancer using e-pharmacophore modeling and molecular dynamics simulations

  2024cites this paper
• The simultaneous use of CRISPR/Cas9 to knock out the PI3Kca gene with radiation to enhance radiosensitivity and inhibit tumor growth in breast cancer

  2024cites this paper
• PIK3CA mutations in endocrine-resistant breast cancer

  2024cites this paper
• HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review

  2024cites this paper
• FOXK2 amplification promotes breast cancer development and chemoresistance.

  2024cites this paper
• Evidence for cytoprotective autophagy in response to HER2-targeted monoclonal antibodies.

  2024cites this paper
• Early evaluation of risk stratification and clinical outcomes for patients with advanced breast cancer through combined monitoring of baseline circulating tumor cells and DNA.

  2024cites this paper
• PI3K Mutation Profiles on Exons 9 (E545K and E542K) and 20 (H1047R) in Mexican Patients With HER-2 Overexpressed Breast Cancer and Its Relevance on Clinical–Pathological and Survival Biological Effects

  2024influential citation
• p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane

  2024cites this paper
• The PI3K/AKT/mTOR signaling pathway in breast cancer: Review of clinical trials and latest advances

  2024cites this paper
• Detection of driver mutations and genomic signatures in endometrial cancers using artificial intelligence algorithms

  2024cites this paper
• AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution

  2024influential citation
• The Importance of Phosphoinositide 3-Kinase in Neuroinflammation

  2024cites this paper
• Highly consistency of PIK3CA mutation spectrum between circulating tumor DNA and paired tissue in lung cancer patients

  2024cites this paper
• Unveiling the Role of PIK3R1 in Cancer: A Comprehensive Review of Regulatory Signaling and Therapeutic Implications.

  2024cites this paper
• Characterization of Expression and Function of the Formins FHOD1, INF2, and DAAM1 in HER2-Positive Breast Cancer

  2023cites this paper
• Network pharmacology-based approach to investigate the molecular targets of essential oil obtained from lavender for treating breast cancer

  2023cites this paper
• Anticancer effects of alpelisib on PIK3CA-mutated canine mammary tumor cell lines

  2023cites this paper
• The Diversity of Liquid Biopsies and Their Potential in Breast Cancer Management

  2023cites this paper
• Genomic determinants in advanced endometrial cancer patients with sustained response to hormonal therapy- case series and review of literature

  2023cites this paper
• Efficacy and safety of first-line treatment for metastatic triple-negative breast cancer: A network meta-analysis

  2023cites this paper
• ER+, HER2− advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes

  2023cites this paper
• Familial CCM Genes Might Not Be Main Drivers for Pathogenesis of Sporadic CCMs-Genetic Similarity between Cancers and Vascular Malformations

  2023cites this paper
• Targeting collagen XVIII improves the efficiency of ErbB inhibitors in breast cancer models

  2023cites this paper
• PIK3CA mutations in breast cancer: A Tunisian series

  2023cites this paper
• Next-Generation Sequencing-Based Analysis of Clinical and Pathological Features of PIK3CA-Mutated Breast Cancer

  2023cites this paper
• Design, synthesis and bioevaluation of PI3Kα-selective inhibitors as potential colorectal cancer drugs.

  2023cites this paper
• The FOXO1 inhibitor AS1842856 triggers apoptosis in glioblastoma multiforme and basal‐like breast cancer cells

  2023cites this paper
• Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy

  2023cites this paper
• Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer

  2023cites this paper
• Collagen XVIII promotes breast cancer through EGFR/ErbB signaling and its ablation improves the efficacy of ErbB-targeting inhibitors

  2022cites this paper
• Reciprocal regulation of Daxx and PIK3CA promotes colorectal cancer cell growth

  2022cites this paper
• Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines

  2022cites this paper
• The Current Staging and Classification Systems of Breast Cancer and Their Pitfalls: Is It Possible to Integrate the Complexity of this Neoplasm into a Unified Staging System?

  2022cites this paper
• An integrated investigation of structural and pathway alteration caused by PIK3CA and TP53 mutations identified in cfDNA of metastatic breast cancer

  2022influential citation
• Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited

  2022cites this paper
• A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions

  2022cites this paper
• Exploring the pharmacological mechanism of compound kushen injection in the treatment of breast cancer using in vitro experiments: Coupling network pharmacology with GEO database

  2022cites this paper
• PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives

  2022cites this paper
• Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα.

  2022cites this paper
• PTEN mutations prevalence in HER2-positive breast cancer patients

  2022cites this paper
• PIK3CA Mutation as Potential Poor Prognostic Marker in Asian Female Breast Cancer Patients Who Received Adjuvant Chemotherapy

  2022cites this paper
• Molecular profiles and circulating tumor-DNA detected in Chinese early stage breast cancer.

  2022cites this paper
• Metabolic Biomarkers in B-Cell Lymphomas for Early Diagnosis and Prediction, as Well as Their Influence on Prognosis and Treatment

  2022cites this paper
• Detection of genetic mutations in patients with breast cancer from Saudi Arabia using Ion AmpliSeq™ Cancer Hotspot Panel v.2.0

  2022cites this paper
• Loss of PTEN Expression, PIK3CA Mutations, and Breast Cancer Survival in the Nurses' Health Studies.

  2022cites this paper
• Cerebral cavernous malformations do not fall in the spectrum of PIK3CA-related overgrowth

  2022cites this paper
• Regulation of Bcl-2 Family Proteins in Estrogen Receptor-Positive Breast Cancer and Their Implications in Endocrine Therapy

  2022cites this paper
• AKT1 and PIK3CA activating mutations in Moroccan bladder cancer patients´ biopsies and matched urine

  2022cites this paper
• Targeted Sequencing of Plasma-Derived vs. Urinary cfDNA from Patients with Triple-Negative Breast Cancer

  2022cites this paper
• Whole Exome Sequencing Identifies Somatic Variants in an Oral Composite Hemangioendothelioma Characterized by YAP1-MAML2 Fusion

  2021cites this paper
• Targeted Therapy in HR+ HER2− Metastatic Breast Cancer: Current Clinical Trials and Their Implications for CDK4/6 Inhibitor Therapy and beyond Treatment Options

  2021cites this paper
• PTEN May Involve in Regulation of PD-L1 Expression in Triple Negative Breast Carcinoma

  2021cites this paper
• Breast Cancer Biomarkers with Clinical Relevance Identified by Massively-parallel DNA and RNA Sequencing

  2021cites this paper
• Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment

  2021cites this paper
• Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients

  2021cites this paper
• Breaking the Silence of Tumor Response: Future Prospects of Targeted Radionuclide Therapy.

  2021cites this paper
• Identification of Pathway-Based Biomarkers with Crosstalk Analysis for Overall Survival Risk Prediction in Breast Cancer

  2021cites this paper
• The INPP4B paradox: Like PTEN, but different.

  2021cites this paper
• Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer

  2021cites this paper
• Transgenic mouse models of breast cancer.

  2021cites this paper
• Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer

  2021cites this paper
• TCRM_A_251668 193..207

  2021cites this paper
• Pattern of Recurrence and Survival in TNBC - A Retrospective Study Done in a Rural Based Medical College and Hospital of West Bengal India

  2021cites this paper
• PIK3CA Mutation Assessment in HR+/HER2− Metastatic Breast Cancer: Overview for Oncology Clinical Practice

  2021cites this paper
• Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer

  2021cites this paper
• Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer

  2021cites this paper
• Nuclear translocation of p85β promotes tumorigenesis of PIK3CA helical domain mutant cancer

  2021cites this paper
• Screening for PIK3CA mutations among Saudi women with ovarian cancer

  2021cites this paper
• Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer

  2021cites this paper
• Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives

  2021cites this paper
• Mutation analysis using cell-free DNA for endocrine therapy in patients with HR+ metastatic breast cancer

  2021cites this paper
• New targets in endocrine-resistant hormone receptor-positive breast cancer.

  2021cites this paper
• PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway

  2021influential citation
• YAP increases response to Trastuzumab in HER2-positive Breast Cancer by enhancing P73-induced apoptosis

  2020cites this paper
• Effect of AKT1 (p. E17K) Hotspot Mutation on Malignant Tumorigenesis and Prognosis

  2020cites this paper
• PI3K Driver Mutations: A Biophysical Membrane-Centric Perspective

  2020cites this paper